While in the medium‐long term AD diagnosis is increasingly likely to rely on biomarkers of amyloid and tau, the present work is highly relevant to current clinical practice, which still places a major focus on the visual assessment of MRI scans. The gene discussed is MAPT; the disease is Alzheimer disease.